AAV & Lentiviral Vector Manufacturing Services

AAV & Lentiviral Vector Services

Elise Biopharma runs AAV Vector Manufacturing and lentiviral programs as engineered, data-governed, and financially disciplined systems. Every phase—from plasmid DNA and upstream amplification to purification, empty/full resolution, formulation, and aseptic fill-finish—is orchestrated under a unified quality architecture. Each decision is tied to a measurable control, ensuring that the final Module 3 reads like an engineered blueprint, not a collection of anecdotes. Sponsors partner with Elise for AAV Vector Manufacturing when timelines, comparability, and inspection outcomes are mission-critical—because our model is unambiguous: define what the product must accomplish in the patient, map those goals to analytically measurable CQAs, and lock process windows that hold steady through scale, raw-material variability, and multi-site production. The outcome is a vector dossier that looks less like a report and more like an investment thesis—assumptions transparent, levers explicit, and downside already mitigated.

Our AAV Vector Manufacturing platform is designed for clarity, reproducibility, and scale agility. Every variable—capsid or pseudotype, genome design, cassette configuration, suspension host, transfection or infection route, and downstream separation logic—is defined early and modeled physically. These molecular and engineering choices are translated into quantifiable parameters: oxygen transfer coefficients, shear budgets, impurity fate maps, and validated hold-time envelopes.

This rigor ensures that a run behaves identically at 2 L, 200 L, or 2 000 L. Digital twins combine mechanistic models (mass transfer, mixing, viscosity, binding) with live campaign telemetry. Soft sensors, off-gas analytics, and historian tags track each run in real time to maintain proven ranges. Orthogonal analytics settle disputes before they become deviations: ddPCR genome counts are reconciled with functional infectivity assays; empty/full ratios are validated by orthogonal physical imagery; and potency is tested in a biologically relevant system rather than an instrument proxy. This is the tone of Elise’s AAV Vector Manufacturing—governed by physics, driven by feedback loops, and documented with precision.

Why Elise Biopharma Leads in AAV Vector Manufacturing

• Integrated design and GMP execution under one digital QMS.
• Dual-site scale coverage (Cambridge MA & Montréal QC) with mirrored PAT infrastructure.
• Proven capsid libraries and cassette optimization pipelines for rare and common serotypes.
• Orthogonal purification trains (affinity, density, mixed-mode) that preserve capsid integrity and deliver regulatory-grade purity.
• Real-time digital twins correlating process kinetics with yield, impurity, and infectivity outcomes.
• Phase-appropriate comparability templates compliant with ICH Q5E/Q12 for rapid change control.
• Stability modeling that ties formulation to route and container closure from day one.

Program Architecture

A robust AAV Vector Manufacturing program behaves like a sequenced transaction with transparent risk and return. We begin by defining the product identity: capsid or pseudotype, tissue tropism, genome length, cassette configuration, dose range, and delivery route. Packaging format—vials, cartridges, or pre-filled syringes—and stability expectations are locked against real logistics constraints, not theoretical storage charts. Platform and scale decisions follow logic, not legacy: AAV in suspension HEK293 for versatility; Sf9/baculovirus for cost efficiency; lentivirus in suspension HEK293 for phase-appropriate output; or adherent systems when biology demands it.

Plasmid DNA supply, whether internal or qualified external, is vetted for supercoil percentage, residual host DNA, antibiotic carryover, and endotoxin levels that pre-empt downstream complexity. Upstream transfection ratios, media composition, and amplification kinetics are fixed with CPP ranges that can survive raw-material variation. Downstream separation—affinity capture, density gradient, or chromatography—is chosen for scalability and validated for empty/full discrimination accuracy. Formulation, filtration, and fill-finish design are written into the control strategy early so that CMC, manufacturing, and clinical logistics converge smoothly. Every parameter maps to a defined CQA with a validated assay and an audit-proof change-control path.

Our execution rhythm distinguishes Elise from conventional CDMOs. Bench studies identify the few parameters that truly move yield, potency, and purity. Targeted DoE campaigns define safe operating zones and deliberate edge-of-failure points that demonstrate robustness. Scale-down reactors replicate the exact hydrodynamics of production vessels—tip-speed, power-per-volume, gas superficial velocity, and headspace dynamics—so predictions hold in the real world. Engineering runs validate those boundaries under GMP conditions, recorded in eBR/MES with full controller decision capture. Once data confirm reproducibility, we freeze the control strategy, initiate formal characterization, and draft the regulatory file concurrently so that documentation evolves alongside execution.

The result is a living manufacturing narrative where every number has context, every assay has lineage, and every process window is defensible. Elise Biopharma’s AAV Vector Manufacturing isn’t just production—it’s precision biology translated into industrial grammar. When speed must coexist with stability, and innovation must meet inspection, Elise remains the benchmark CDMO for next-generation viral vectors.

Decision Framework

For AAV, we align capsid family and promoter to the therapeutic window and supply plan. Genome length and ITR integrity are checked early; too many teams discover packaging problems by accident. Host platform is a first-order decision: suspension HEK293 with transient transfection for speed and flexibility; Sf9/baculovirus for cost-per-dose once design is stable and process economics justify the setup. Transfection reagent, plasmid ratios, viable cell density at transfection, temperature-shift policy, and oxygen strategy form the HEK stack; MOI, infection timing, and baculovirus stability drive the Sf9 stack. Downstream is decided before upstream begins: affinity versus ion-exchange capture, polishing to remove aggregates and process contaminants, and explicit empty/full separation logic (density gradient versus affinity/anion exchange variants) with acceptance criteria tied to potency. The most expensive error in AAV is to defer empty/full until late; we refuse that trap.

For lentivirus, pseudotype (often VSV-G) and cassette are fixed first. Architecture (2-, 3-, or 4-plasmid) is chosen for biosafety and yield, with producer-line development reserved for programs with long runways. Suspension hosts are standard for scale; adherent is used where biology or facility requires it. Perfusion is considered when productivity and economics win decisively after shear and foam penalties are priced in. Biosafety is not a line in a slide; RCL testing strategy, segregation, and environmental monitoring are defined up front.

Across both modalities, plasmids are treated as a separate vertical. Supercoiled percentage, residual host DNA, residual antibiotic, endotoxin, and sequencing integrity are the starting metrics. We qualify nuclease pathways and confirm that plasmid impurities do not propagate into false positives downstream. Every plasmid change has a pre-written comparability scaffold; you do not discover a bridge while standing on it.

Plasmid DNA Supply and Control

Every flawless vector begins with DNA that behaves beautifully. At Elise Biopharma, AAV Vector Manufacturing and lentiviral programs start with plasmids engineered for consistency—refined, responsive, and completely predictable. For research and IVT grades, we sculpt supercoiled purity and residual DNA targets to keep transfection performance sensual in its precision; for GMP campaigns, we layer in DMF-ready documentation and ruthless endotoxin specifications that leave nothing to chance.

Our host systems are chosen like perfect dance partners—low nuclease, low endotoxin, biologically graceful. Growth and lysis are timed by inline conductivity and UV absorption instead of superstition or stopwatch, while detergent-light polishing keeps resins from losing their touch across campaigns. For HEK-based AAV Vector Manufacturing, our three-plasmid choreography is tuned by mass and molar ratios under design-of-experiment logic so that every contributor to genome yield and impurity formation is defined, not guessed. In lentivirus mode, packaging and transfer plasmids are validated by restriction mapping, sequencing-adjacent confirmation, and when philosophy allows, antibiotic-free selection. Every lot lives in our eBR genealogy, traceable and inspection-ready, like a molecular family tree written in perfect order.

Comparability lives at the plasmid tier. We define acceptance bands for supercoil %, residual DNA, antibiotic traces, and endotoxin—all linked empirically to transfection performance and downstream purity. When a supplier alters a resin or buffer component, Elise runs precise sensitivity studies within change control, adjusts CPPs with restraint, and documents every justification. Nothing improvisational, nothing opaque—just process intimacy rendered as control.

Why Elise Biopharma Leads in Plasmid and AAV Vector Manufacturing

• Predictive plasmid analytics linking supercoil state to transfection efficiency.
• Closed-loop fermentation monitored by capacitance and UV signals—no manual guesswork.
• Proprietary detergent-light lysis protecting resin longevity and purity.
• Internal or qualified external GMP DNA supply with DMF cross-reference packages.
• Phase-appropriate comparability and traceability embedded in eBR genealogy.
• Dual plasmid/lentiviral compatibility workflows engineered to FDA and EMA harmonization.

AAV Manufacturing: Upstream

The upstream is where elegance meets control. In Elise Biopharma’s AAV Vector Manufacturing, suspension HEK293 and Sf9/baculovirus platforms operate under oxygen, heat, and shear budgets that are modeled—not hoped for. Transient transfection is parameterized like choreography: plasmid mass ratios, reagent charge, viable cell density at transfection, complexation temperature, and shift timing. Each parameter finds its rhythm in data. Our multivariable controller synchronizes aeration, agitation, and back-pressure, adjusting oxygen enrichment with the subtlety of a conductor guiding a symphony. Capacitance and off-gas inflections decide transfection windows—not calendars. Feeds flow when heat and oxygen demand justify them, not when tradition whispers they should. It’s science, not superstition.

In Sf9 cultures, baculovirus stock quality is measured to three significant figures, multiplicity of infection (MOI) is tuned to align capsid expression with genome replication, and infection timing is chosen by cell physiology rather than arbitrary clock hours. We select agitation and sparging hardware that achieve perfect gas–liquid intimacy without bruising cells or distorting hydrodynamics. A digital twin predicts OUR, CTR, and heat load across scales; if the model doesn’t approve, neither do we.

Harvest becomes an art of restraint—pulled exactly when vector genome yield peaks and protease markers whisper their warning. We track vg/mL, viability, and metabolic signature continuously, never waiting for the culture to fail before we move. Clarification follows kinetics, not ritual; filterability indices and shear ceilings shape every decision. Nuclease treatment is validated with downstream clearance evidence so residual DNA is a solved equation, not a mystery. Every hold is explicit, time and temperature tested so schedulers aren’t making scientific decisions on a Friday night.

Upstream Excellence at Elise Biopharma

• Advanced PAT integration for real-time pH, DO, and osmolality balancing.
• Predictive transfection modeling for scalable yield optimization.
• Multi-serotype compatibility across AAV2, 5, 8, 9, rh10, and emerging variants.
• Integrated baculovirus infection kinetics linked to automated MOI control.
• Inline heat and shear modeling preventing capsid denaturation at scale.

AAV Manufacturing: Downstream

Downstream is where purity meets seduction—the transformation of chaotic lysate into a refined, potent substance. In AAV Vector Manufacturing, Elise Biopharma treats capture and polish not as steps, but as a dialogue between physics and biology.

Affinity resins are deployed where they create measurable value; ion-exchange is tuned by pI and conductivity to bind firmly and release predictably. Mixed-mode and IEX polishing remove aggregates and process residues with orthogonal grace, data always leading fashion. Every column has its own capacity model accounting for antifoam exposure and resin aging, while guard beds stand ready to absorb trouble before it touches the product. Buffers follow simulated conductivity and pH trajectories proven at pilot scale so GMP never meets surprise precipitation.

Empty/full separation gets the respect it deserves. Density gradients seduce with resolution but not always with scalability, so Elise validates affinity and anion-exchange alternatives that deliver identical biological truth.

A primary method is paired with a cross-check validated by physical imagery—two voices singing the same result. Acceptance limits reflect potency and clinical economics, not vanity metrics. When potency data show that 90% “full” performs identically to 95%, we do not chase the ghost of perfection; we bank the win and move forward.

Ultrafiltration and diafiltration steps are calibrated like touch—minimal shear, minimal loss, maximum preservation. Membrane chemistry is screened for adsorption risk; flow and pressure profiles are validated for gentleness. Sterile filtration is managed as a controlled caress, not a blunt endpoint—flow, pressure, and contact time all measured, all justified. Hold-time envelopes are defined explicitly so the product never lingers too long. The drug substance that emerges from Elise’s AAV Vector Manufacturing suites is poised, consistent, and regulator-ready—exactly as designed at 2 L, 200 L, and 2 000 L.

Downstream Innovations that Define Elise Biopharma

• Orthogonal purification pipelines tuned by capsid charge and isoelectric point.
• Data-anchored empty/full separation using AEX or affinity over density when justified.
• Multi-cycle resin aging models predicting performance through PPQ campaigns.
• Dynamic buffer modeling that preempts aggregation and precipitation events.
• Closed, automated UF/DF systems preserving vector integrity under gentle shear.
• Sterile filtration validated for flow symmetry and capsid retention efficiency.

At Elise Biopharma, AAV Vector Manufacturing is not a process—it’s performance art executed under cGMP. Every movement, every variable, every parameter has purpose. From plasmid to particle, we choreograph biology into something deliberate, repeatable, and—yes—beautiful.

AAV Analytics

Analytics decide credibility. Vector genome titer is measured by ddPCR with assays that recognize the right junctions and avoid counting irrelevant species; whenever possible, we include an orthogonal method. Infectivity is measured by a functional assay that maps to the real mechanism; we do not accept a convenient surrogate when it divorces titer from effect. Empty/full ratios are quantified by methods that agree with analytical ultracentrifugation or electron microscopy at chosen checkpoints; charge-based or affinity surrogates are validated against physical truth, not just against themselves. Identity is confirmed by LC-MS peptide mapping for capsid and by sequencing-adjacent checks for the genome; ITR integrity is not assumed.

Process residuals—host-cell DNA, host-cell proteins, residual nuclease, residual solvent if present—are measured with methods that hit the file’s claimed sensitivity and are repeated at meaningful points in the process so failure is detected upstream of release. Adventitious agent testing, mycoplasma, sterility, and endotoxin follow phase-appropriate frameworks and are documented in a way that does not force a reviewer to reverse-engineer intent.

Stability tells operations what is allowed. Real-time, accelerated, and freeze–thaw studies are run with intervals and acceptance criteria that match the clinical plan. If a vector will see two freeze–thaw cycles before dosing, we test three and set a policy that eliminates guesswork. Photostability, container compatibility, subvisible particles, and shipping simulation are treated as operational engineering problems with data, not as afterthoughts. All of this is captured in the eBR/MES with ALCOA+ discipline so inspection is a reading exercise rather than an archeological dig.

AAV Cost Discipline and Throughput Planning

Vector manufacturing must compete for capital. We model cost-of-goods with a focus on the variables that compound: plasmid cost and quality, transfection reagent cost and dose, resin performance over lifetime, antifoam impact on chromatography, and yield penalties from over-aggressive separation goals. We avoid dollar leaks by enforcing oxygen and heat budgets that keep productivity in a stable band, by standardizing buffer recipes that do not compromise performance, and by choosing fill-finish formats that match the real consumption pattern. We track OEE for critical equipment, schedule buffer and media prep to prevent hidden bottlenecks, and quantify the carrying cost of hold times so scheduling decisions are priced honestly.

Process Characterization and Validation for AAV

Characterization is not a formality; it is the evidence that scale and time will not undermine the file. We design experiments to expose sensitivity of CQAs to the levers that matter—plasmid ratio, VCD at transfection, temperature and DO policy, nuclease dose and time, capture pH and conductivity, flow rates through shear-sensitive steps, and the parameters that control empty/full resolution. Multivariate analysis clarifies interactions; we do not commit to ranges that only hold on a good day. Validation packages include IQ/OQ/PQ for critical equipment, method validation for analytics with system suitability and bracketing, and soft-sensor validation with residual-based alarms and a re-qualification schedule. PPQ is not theater; it proves that the process can hold control under normal variability, not just when everyone is staring at it.

Digital Twins, PAT, and Data Integrity for AAV

The twin is a quality tool, not a novelty. Mechanistic mass- and energy-balances, oxygen transfer predictions, and mixing models are layered with machine-learning shells that capture plant idiosyncrasies. The model reads Raman/FTIR, off-gas mass spectrometry, capacitance, and historian tags and recommends bounded moves; when residuals exceed limits, it raises an alarm and retracts to conservative behavior. Inline and at-line measurements (e.g., DLS for size during LNP mixing in combination programs, conductivity and UV during chromatography, pressure and flow during filtration) are tied to batch logic so setpoints are documented with reasons, not just values. eBR/MES enforces ALCOA+; the auditor can reconstruct why a feed trajectory shifted, what uncertainty was assumed, and how that affected release. We do not claim “digital” unless it shortens reviews, prevents deviations, or saves money you can measure.

Transition to Lentiviral Manufacturing

Elise Biopharma approaches Lentiviral Manufacturing with the same engineering precision and predictive discipline that made it a leader in AAV Vector Manufacturing. Lentiviral vectors are biologically fragile and operationally unforgiving—short half-lives, envelope instability, and BSL-2 containment create a process environment where improvisation costs viability, potency, and time. We built our Lentiviral Manufacturing platform to handle that volatility through design logic, digital oversight, and analytics that make uncertainty measurable rather than mysterious.

Suspension HEK293 remains the industrial backbone for Lentiviral Manufacturing because it balances transient productivity with scalability, while producer-line architectures are justified only when lifetime economics prove the case. Elise’s digital twins model transfection kinetics, gas–liquid shear, and foam behavior under real campaign conditions, identifying mechanical or metabolic choke points before scale. Perfusion is introduced not as a fad but as a validated economic decision: only when productivity per reactor-hour, adjusted for shear, filtration burden, and cost per dose, outperforms batch does it graduate to the master plan.

Each operation—transfection, harvest, clarification, and purification—is tuned for envelope protection and infectivity preservation. Residual plasmid DNA, nuclease, and transfection reagents are quantified by validated assays with spike-recovery and LOQ data that stand up in audits. Replication-competent lentivirus (RCL) testing runs under dual-mode (qPCR plus culture-based) sensitivity verified to regulatory expectation. Cryostable formulation is designed in parallel with manufacturing, tested for viscosity, glide force, and reconstitution kinetics so clinics can execute dosing without improvisation. Every step in Elise’s Lentiviral Manufacturing platform is measured, modeled, and pre-justified—because process robustness is not luck; it’s a design variable.

Lentiviral Manufacturing — Upstream

We treat upstream like a flight plan. Every input—plasmid ratio, charge complexation, viable cell density, osmolality, and dissolved oxygen—is tested through compact DoE grids that define edge-of-failure ranges. Bubble-induced shear is quantified and neutralized through gas-shear modeling and controlled backpressure regimes. When we convert a process to a producer line, comparability is written in advance: analytical envelopes, statistical equivalence ranges, and assay continuity are already in place. Perfusion operations use capillary-controlled aeration and shear-bounded TFF to maintain viral yield while cutting media waste. Harvest timing is defined kinetically, not by calendar—an hour too long is a logarithmic loss. For Elise, Lentiviral Manufacturing means knowing when to stop as precisely as knowing how to start.

Downstream Engineering for Lentiviral Manufacturing

Our downstream design starts where infectivity meets purity. Tangential-flow ultrafiltration and diafiltration use membrane chemistries screened for minimal adsorption; pressure and shear limits are validated at full-scale hardware load, not bench approximations. AAV-grade AEX membranes are repurposed with modified conductivity and residence-time envelopes for lentivirus, giving high DNA and protein clearance without compromising envelope proteins. We validate recovery, not just yield, because only infectious particles count. Sterile filtration uses wide-bore membranes and predictive flow-rate modeling so the last operation doesn’t become the highest risk. Cryostability work tests each container closure under temperature excursions and freeze–thaw cycles that reflect clinical practice, not ideal storage. These details are why Elise Biopharma’s Lentiviral Manufacturing processes consistently pass inspection without rework.

Analytics — Quantifying Function in Lentiviral Manufacturing

Functional titer is our central metric. Transducing units per milliliter (TU/mL) are measured in cell-based assays aligned to the cassette’s biology. Where fluorescence or selectable markers are absent, ddPCR quantifies integrated copy number with standard curves validated by secondary reference material. Physical titer correlates—p24 ELISA and genome copies—are monitored but never mistaken for function. Host-cell protein and DNA clearance are confirmed through LC–MS and qPCR, tied to risk-based phase expectations. RCL panels combine molecular and culture confirmation, each with spike-recovery proof of detection. Envelope specificity, identity mapping (gag/pol peptides), and pseudotype confirmation complete the dossier. Stability analytics define short-term 2–8 °C holds, multi-thaw behavior, and cumulative RT exposure so scheduling is guided by data, not hope. This layered testing is what makes Elise’s Lentiviral Manufacturing programs defensible at every review.

Digital Control and PAT Integration

In Elise Biopharma’s facilities, every lentiviral campaign runs under real-time supervision. Electrode drift, capacitance lag, and thermal noise are modeled, not ignored. Off-gas MS reports OUR/CTR that trigger feed and aeration automatically; chromatography systems calculate resin breakthrough before it happens; TFF skids enforce shear and transmembrane pressure boundaries with automatic soft-stop routines. eBR/MES records not only that a range was respected but why—the control decision, algorithmic rationale, and model confidence interval. This closed-loop intelligence distinguishes Elise’s Lentiviral Manufacturing and aligns it with the same predictive backbone that defines our AAV Vector Manufacturing lines.

Regulatory Logic and Lifecycle Management

We build the regulatory file like a control story. The QTPP defines what the lentiviral product must achieve in patients—potency, purity, and stability. CQAs link directly to measurable assays, and CPPs are chosen for true leverage. Compact DoEs and edge-of-failure data define ranges that survive scale, raw-material drift, and site change. Method lifecycle follows ICH Q2(R2); viral safety complies with ICH Q5A, while comparability is prewritten under Q5E with ICH Q12 hooks for future site or supplier moves. For HEK-based production we demonstrate RCL control and residual plasmid risk; for adherent or Sf9 systems we specify matrix-specific viral panels. This proactive authorship is why reviewers see Elise’s Lentiviral Manufacturing files as engineered systems rather than speculative biology.

Economic and Throughput Modeling

Lentiviral programs succeed when economics align with physics. Elise models cost per dose by integrating plasmid consumption, transfection reagent efficiency, perfusion cycle duration, filtration lifespan, and QC throughput. Perfusion gains are balanced against shear costs and filtration burdens; media scheduling eliminates hidden downtime. OEE dashboards monitor upstream, downstream, and isolator utilization.

These analyses feed directly into investor-facing materials and IND submissions, proving that our Lentiviral Manufacturing delivers both scientific and financial clarity.

Supply Assurance and Risk Architecture

Every critical input in Lentiviral Manufacturing—plasmid DNA, enzymes, media, membranes—is dual-sourced or buffered with qualified safety stock. Cell banks and viral seeds reside in mirrored biorepositories across regions, with genealogy visible through QA dashboards. Supplier notifications trigger sensitivity studies under change control, executed within predefined analytical templates. Solvent recycling and closed-loop water systems reduce environmental and economic footprint, reinforcing Elise’s reliability at every scale.

Top 20 FAQ — AAV Vector Manufacturing

1. What makes Elise Biopharma a global leader in AAV Vector Manufacturing?
Elise Biopharma dominates AAV Vector Manufacturing because we operate at the intersection of design precision, analytical depth, and industrial reproducibility. Our dual GMP hubs in Cambridge, MA, and Montréal, QC, house integrated plasmid DNA, HEK293, and Sf9 platforms under a unified digital QMS. We fuse digital twins, PAT, and eBR/MES systems so every AAV batch behaves identically across scales. Our process couples regulatory readiness (ICH Q2, Q5A, Q12) with predictive analytics, resulting in inspection-proof filings and accelerated clinical timelines.

2. What types of AAV serotypes do you specialize in producing?
We manufacture all leading AAV serotypes—AAV1, AAV2, AAV5, AAV8, AAV9, and rh10—along with emerging capsid variants and proprietary pseudotypes. Each capsid’s charge, tropism, and isoelectric profile is modeled early in development to determine which purification and polishing workflows fit its physicochemical signature. This ensures that every AAV Vector Manufacturing campaign is optimized for potency, yield, and tissue specificity.

3. How does Elise control plasmid DNA quality for AAV Vector Manufacturing?
Plasmids are engineered and qualified to GMP-grade specifications, with supercoil ≥ 95%, endotoxin ≤ 0.05 EU/µg, and residual host DNA < 1%. Inline monitoring governs growth and lysis, while detergent-light purification preserves resin life and purity. Our plasmid genealogy system ties every lot to analytical fingerprints and change-control records, ensuring perfect traceability across programs.

4. What expression platforms are used for AAV production?
Elise offers both HEK293 transient transfection and Sf9/baculovirus platforms. HEK293 systems excel for flexibility and rapid scale-up; Sf9 provides high-volume economics for commercial supply. Both are validated to 2,000 L scale with oxygen transfer, mixing, and heat budgets fully characterized by digital twins. We advise clients based on clinical phase, dose economics, and capsid stability.

5. How does Elise manage transient transfection efficiency in HEK293 systems?
We control transfection like an orchestration—plasmid ratios, charge density, VCD, osmolality, and transfection timing are modeled under design-of-experiments. A multivariate controller integrates DO, pH, and temperature feedback to maintain ideal complexation and expression. Our AAV Vector Manufacturing platform routinely achieves vg yields exceeding 1E15 with CV <10% across replicates.

6. What about MOI and infection control in Sf9/baculovirus systems?
For Sf9-based AAV Vector Manufacturing, Elise synchronizes MOI to ensure genome replication and capsid expression remain in lockstep. We validate baculovirus stock integrity by titer, ratio, and infectivity before every campaign. Infection timing and agitation regimes are optimized to minimize shear, preserve cell viability, and deliver reproducible vector quality at scale.

7. How do you optimize empty/full capsid separation?
Empty/full discrimination is designed from the start, not retrofitted later. Elise uses gradient-free anion-exchange chromatography or affinity variants validated by physical EM and analytical ultracentrifugation. Acceptance bands are tied to potency and dose economics—not vanity purity thresholds. We prefer methods that scale cleanly without yield collapse, maintaining full reproducibility across PPQ campaigns.

8. How is potency verified for AAV drug substance?
Potency is measured on relevant cell models, not instruments. We pair ddPCR-based genome quantification with functional infectivity assays that mirror the target tissue or indication. This ensures potency in our AAV Vector Manufacturing data correlates directly to biological activity in vivo, reducing post-approval comparability risk.

9. How do you minimize shear and aggregation in downstream processing?
Downstream is designed around gentleness. Tangential-flow filtration, anion-exchange, and polishing steps operate within validated shear envelopes. Membrane chemistries are screened for adsorption risk, while pressure profiles are controlled to preserve envelope integrity. Buffers follow conductivity and pH trajectories modeled via simulation before production.

10. Can Elise manufacture AAV vectors under full GMP compliance?
Yes. Our AAV Vector Manufacturing suites are ISO-classified, FDA-registered, and follow GMP aligned to ICH Q7, Q5A, and 21 CFR Parts 210–211. Digital batch records, validated analytical methods, and audit-ready SOPs ensure complete regulatory compliance for Phase I through commercial supply.

11. What analytics are used to characterize AAV quality?
We deploy orthogonal assays: ddPCR for genome titer, ELISA for capsid quantification, CE-SDS and SEC-MALS for purity, TEM for morphology, and AEX/HPLC for full/empty profiles. Residual DNA and HCP are monitored by qPCR and LC–MS, ensuring that AAV Vector Manufacturing outputs are scientifically and regulatorily defensible.

12. How does Elise ensure batch-to-batch reproducibility?
Reproducibility is built into our AAV Vector Manufacturing digital framework. Every reactor, mixer, and chromatography skid is modeled by digital twins correlating process parameters to quality outputs. Real-time PAT sensors track off-gas, pH, and conductivity, feeding predictive control algorithms that hold CQAs within ±5% tolerance.

13. What stability studies support AAV products?
We perform ICH-compliant stability programs at −80 °C, −20 °C, and 2–8 °C with defined excursion studies. Freeze–thaw and room-temperature holds are qualified for potency retention and particle size drift ≤5%. Lyophilized formats undergo Tg′ mapping, collapse testing, and reconstitution validation.

14. How does Elise handle comparability for process or site changes?
Comparability is prewritten under ICH Q5E/Q12. When a raw material, site, or capsid changes, Elise executes bridging runs with pre-justified acceptance criteria—identity, purity, potency, and safety metrics already defined. This lifecycle discipline makes our AAV Vector Manufacturing pathways regulator-friendly and delay-proof.

15. Do you offer fill-finish for AAV drug product?
Yes. We operate ISO 5 robotic isolators with nitrogen overlays, 100% in-line weight checks, and container-closure integrity verification. Presentations include cryo-capable vials, PFS, and cartridges validated for freeze–thaw resilience. Labels, diluents, and handling instructions are written from the clinic backward for practical execution.

16. How does Elise manage endotoxin and impurity control?
We design purification trains to achieve <0.1 EU/mg endotoxin and residual DNA <10 pg/µg. Affinity capture, anion-exchange, and polishing are tuned to remove contaminants without damaging capsids. Our impurity clearance maps are submitted with real downstream data, not theoretical claims.

17. How do you integrate PAT and AI into AAV Vector Manufacturing?
Elise’s AAV Vector Manufacturing uses AI-enhanced PAT. Raman, FTIR, and off-gas MS models feed predictive analytics that forecast deviations before they manifest. Residual-based alarms trigger interventions automatically. AI-driven optimization aligns productivity, quality, and cost to maintain regulatory control and operational elegance.

18. What’s your approach to cost modeling and scalability?
We make vector economics transparent. Elise models COGS as a function of plasmid consumption, resin lifetime, filtration throughput, and QC sampling cost. Digital twins simulate capacity utilization to remove hidden bottlenecks. This makes scale-up predictable and financially credible for investors and partners.

19. What sustainability practices are built into AAV Vector Manufacturing?
Environmental responsibility is built into design, not added later. Solvent-recovery loops, closed-water systems, and heat-load optimization reduce carbon intensity by up to 30%. Each sustainability improvement correlates directly to process efficiency—cleaner science is also cheaper science.

20. How can potential partners engage with Elise Biopharma?
Our engagement model begins with a Design-to-Proof sprint: gRNA/plasmid alignment, transfection model, separation logic, and early analytics. Within 60 days, clients receive a risk ledger, mini-DoE, and control strategy draft. Gene-to-IND follows with dossier assembly and PPQ planning. At every stage, Elise’s AAV Vector Manufacturing platform ensures the same deliverables: truth, reproducibility, and timelines that hold.

Lentiviral Manufacturing as a Discipline

In Elise Biopharma’s hands, Lentiviral Manufacturing ceases to be experimental and becomes predictable engineering. Every attribute—infectivity, potency, purity, stability—is quantified by validated, regulator-credible assays. Every process variable is mapped to physics and economics. The outcome is a manufacturing and regulatory framework that delivers consistent product, inspection-ready data, and timelines you can believe.

This is why global sponsors entrust their most complex viral programs to Elise Biopharma. We bridge creativity with control, speed with accuracy, and innovation with compliance. Lentiviral Manufacturing at Elise is not just how vectors are made—it’s how gene therapy manufacturing becomes industrial, auditable, and enduring.

Contact our team directly at info@elisebiopharma.com